Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have earned an average rating of “Buy” from the nine research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $27.33.
KALV has been the topic of a number of research reports. ValuEngine upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research upgraded Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research report on Wednesday, September 12th. Cantor Fitzgerald initiated coverage on Kalvista Pharmaceuticals in a research report on Friday, September 21st. They set an “overweight” rating and a $32.00 price objective on the stock. BidaskClub lowered Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 9th. Finally, Stifel Nicolaus initiated coverage on Kalvista Pharmaceuticals in a research report on Monday, October 15th. They set a “buy” rating on the stock.
Shares of KALV opened at $18.82 on Friday. Kalvista Pharmaceuticals has a 52-week low of $7.73 and a 52-week high of $23.97. The firm has a market capitalization of $316.09 million, a PE ratio of -12.30 and a beta of 2.87.
Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.14). Kalvista Pharmaceuticals had a negative net margin of 132.38% and a negative return on equity of 56.24%. The business had revenue of $3.72 million during the quarter, compared to the consensus estimate of $4.11 million. On average, sell-side analysts expect that Kalvista Pharmaceuticals will post -2.07 earnings per share for the current year.
In other news, Director Albert Cha acquired 1,058,824 shares of Kalvista Pharmaceuticals stock in a transaction that occurred on Monday, September 10th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $18,000,008.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 49.10% of the company’s stock.
A number of hedge funds have recently modified their holdings of KALV. Spark Investment Management LLC bought a new stake in Kalvista Pharmaceuticals during the 2nd quarter worth $108,000. Stanley Laman Group Ltd. lifted its holdings in Kalvista Pharmaceuticals by 48.3% during the 2nd quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock worth $545,000 after buying an additional 21,861 shares during the period. BlackRock Inc. lifted its holdings in Kalvista Pharmaceuticals by 203.8% during the 2nd quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 10,871 shares during the period. DRW Securities LLC lifted its holdings in Kalvista Pharmaceuticals by 37.3% during the 2nd quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock worth $167,000 after buying an additional 5,600 shares during the period. Finally, Interwest Venture Management Co. lifted its holdings in Kalvista Pharmaceuticals by 17.8% during the 3rd quarter. Interwest Venture Management Co. now owns 388,766 shares of the specialty pharmaceutical company’s stock worth $8,596,000 after buying an additional 58,824 shares during the period. Institutional investors and hedge funds own 37.12% of the company’s stock.
About Kalvista Pharmaceuticals
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.